Protocol No.: NRG-GY026

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-OYSK (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Principal Investigator
Pfaendler, Krista
Phase
II/III
Age Group
Adult
Applicable Disease Site
Gynecologic Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Carla Ross, RN
Senior Research Nurse
Phone: +1 304-293-2633

View on ClinicalTrials.gov